China Cord Blood Corp. | Income Statement

Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
93,630.50
102,525.90
104,245.90
112,944.60
141,347.30
147,025.30
Cost of Goods Sold (COGS) incl. D&A
19,698.20
23,855.70
25,209.50
23,573.00
29,784.90
27,717.80
Gross Income
73,932.30
78,670.20
79,036.40
89,371.60
111,562.40
119,307.40
SG&A Expense
36,025.20
40,735.50
48,952.90
53,919.50
69,334.40
62,441
EBIT
37,907.10
37,934.70
30,083.60
35,452.10
42,228.10
56,866.50
Unusual Expense
-
-
1,314.60
376.40
-
8,511.60
Non Operating Income/Expense
1,994.50
480.10
7,565.00
4,799.80
753.40
984.70
Interest Expense
11,453.40
16,320.60
16,976.10
17,747.40
491.40
-
Pretax Income
31,205.50
25,040.60
22,222.30
24,716.40
45,799.90
53,112.30
Income Tax
9,544.90
7,639.90
7,861.70
5,591.20
9,454.10
9,127.70
Consolidated Net Income
19,200.80
16,091.90
14,360.60
17,636.20
36,345.80
43,984.60
Net Income
19,099.00
16,011.00
14,303.60
17,264.80
35,775.30
43,377.20
Net Income After Extraordinaries
19,099.00
16,011.00
14,303.60
17,264.80
35,775.30
43,377.20
Net Income Available to Common
19,099.00
16,011.00
14,303.60
17,264.80
35,775.30
43,377.20
EPS (Basic)
0.26
0.22
0.20
0.24
0.32
0.36
Basic Shares Outstanding
73,003.20
73,003.20
73,003.20
73,003.20
112,938.60
-
EPS (Diluted)
0.26
0.22
0.20
0.24
0.30
-
Diluted Shares Outstanding
73,003.20
73,003.20
73,003.20
73,003.20
119,329.40
-
EBITDA
43,965.20
46,104.40
37,971.30
42,954.40
49,861.50
64,668.80
Non-Operating Interest Income
2,757.30
2,946.40
2,864.50
2,588.30
3,309.90
3,772.70
Minority Interest Expense
101.80
80.90
57.10
371.40
570.50
607.50
Other After Tax Income (Expense)
2,459.80
1,308.90
-
1,489.00
-
-

About China Cord Blood

View Profile
Address
48th Floor, Bank of China Tower
Hong Kong
Hong Kong
Employees -
Website http://www.globalcordbloodcorp.com
Updated 07/08/2019
Global Cord Blood operates ass a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies such as cord blood transplants. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.